Teva Pharmaceutical Industries Limited (NYSE:TEVA) said that it may consider acquiring Celltrion Pharm Inc. (KOSDAQ:A068270) as an option to strengthen its biosimilar portfolio. "We will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners," Yonatan Beker, Director of corporate reputation at Teva Pharmaceutical told The Investor via email on October 14, 2016.